U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with M

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
138017 Q2 2022 METHYLPARABEN BUCCAL FILM, SOLUBLE 3mg Correction
138018 Q3 2022 METHYLPARABEN BUCCAL FILM, SOLUBLE 3mg Correction
138113 Q3 2022 MANNITOL INTRAVENOUS LIQUID 4.05 %w/v Deletion
138114 Q3 2022 MEDIUM-CHAIN TRIGLYCERIDES SUBLINGUAL SPRAY 36.70 mg Deletion
138299 Q2 2022 MAGNESIUM OXIDE ORAL TABLET, DELAYED RELEASE 367.86 mg MDE Replacement
138300 Q3 2022 MAGNESIUM OXIDE ORAL TABLET, DELAYED RELEASE 368mg MDE Replacement
138301 Q2 2022 MAGNESIUM STEARATE ORAL GRANULE, FOR SUSPENSION 7.00 mg MDE Replacement
138302 Q3 2022 MAGNESIUM STEARATE ORAL GRANULE, FOR SUSPENSION 14mg MDE Replacement
138303 Q2 2022 MALTODEXTRIN ORAL PASTE 35.00 mg/ 1.00 ml MDE Replacement
138304 Q3 2022 MALTODEXTRIN ORAL PASTE 1050mg MDE Replacement
138305 Q2 2022 MANNITOL INTRAVENOUS INJECTION, POWDER, FOR SOLUTION 750 mg MDE Replacement
138306 Q3 2022 MANNITOL INTRAVENOUS INJECTION, POWDER, FOR SOLUTION 794mg MDE Replacement
138307 Q2 2022 MANNITOL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3850.00 mg MDE Replacement
138308 Q3 2022 MANNITOL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15400mg MDE Replacement
138309 Q2 2022 MANNITOL INTRAVENOUS SOLUTION 4.15 %w/v MDE Replacement
138310 Q3 2022 MANNITOL INTRAVENOUS SOLUTION 15400mg MDE Replacement
138311 Q2 2022 MANNITOL ORAL POWDER 1100.00 mg MDE Replacement
138312 Q3 2022 MANNITOL ORAL POWDER 4663mg MDE Replacement
138313 Q2 2022 MANNITOL SUBCUTANEOUS INJECTION, POWDER, FOR SOLUTION 20 mg MDE Replacement
138314 Q3 2022 MANNITOL SUBCUTANEOUS INJECTION, POWDER, FOR SOLUTION 23mg MDE Replacement
138315 Q2 2022 MANNITOL SUBLINGUAL TABLET, ORALLY DISINTEGRATING 10.25 mg MDE Replacement
138316 Q3 2022 MANNITOL SUBLINGUAL TABLET, ORALLY DISINTEGRATING 10mg MDE Replacement
138317 Q2 2022 MEDIUM-CHAIN TRIGLYCERIDES ORAL CAPSULE, EXTENDED RELEASE 3.08 mg MDE Replacement
138318 Q3 2022 MEDIUM-CHAIN TRIGLYCERIDES ORAL CAPSULE, EXTENDED RELEASE 5mg MDE Replacement
138319 Q2 2022 MENTHOL ORAL LOZENGE 0.94 mg MDE Replacement
138320 Q3 2022 MENTHOL ORAL LOZENGE 23mg MDE Replacement
138321 Q2 2022 MENTHOL SUBLINGUAL TABLET 2.00 mg MDE Replacement
138322 Q3 2022 MENTHOL SUBLINGUAL TABLET 2mg MDE Replacement
138323 Q2 2022 METHYL GLUCOSE SESQUISTEARATE TOPICAL CREAM, AUGMENTED 3.50 %w/w MDE Replacement
138324 Q3 2022 METHYL GLUCOSE SESQUISTEARATE TOPICAL CREAM, AUGMENTED 70mg MDE Replacement
138325 Q2 2022 METHYLPARABEN TOPICAL CREAM, AUGMENTED 0.20 %w/w MDE Replacement
138326 Q3 2022 METHYLPARABEN TOPICAL CREAM, AUGMENTED 2mg MDE Replacement
138327 Q2 2022 METHYLPARABEN SODIUM ORAL SOLUTION 2.60 mg/ 1.00 ml MDE Replacement
138328 Q3 2022 METHYLPARABEN SODIUM ORAL SOLUTION 104mg MDE Replacement
138329 Q2 2022 MONO AND DIGLYCERIDE TOPICAL CREAM 15.00 %w/w MDE Replacement
138330 Q3 2022 MONO AND DIGLYCERIDE TOPICAL CREAM 300mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: July 1, 2022
Database Last Updated: July 18, 2022

Back to Top